首页> 外文期刊>American pharmaceutical review >Comparative Human In-Vivo Study of an Immediate Release Tablet Over-Encapsulated by Gelatin and Hydroxypropyl Methyl Cellulose Capsules-Impact Of Dissolution Rate on Bioequivalence
【24h】

Comparative Human In-Vivo Study of an Immediate Release Tablet Over-Encapsulated by Gelatin and Hydroxypropyl Methyl Cellulose Capsules-Impact Of Dissolution Rate on Bioequivalence

机译:明胶和羟丙基甲基纤维素胶囊过度包裹的速释片剂的比较人体内研究-溶出度对生物等效性的影响

获取原文
获取原文并翻译 | 示例
       

摘要

Rapid and consistent in-vivo drug dissolution is critical for drug absorption. In-vitro dissolution tests are used to predict in-vivo disintegration and dissolution properties of drug products. The in-vitro disintegration and dissolution times of tablets and capsules can vary significantly based on their composition and processing. Though small differences in-vitro dissolution are not expected to result in significant in-vivo performance differences, the slight in-vitro dissolution delay observed by over-encapsulation for double blind clinical trials, as well as switching from gelatin to HPMC capsules often raises concerns on the potential impact on in-vivo bioavailability. While it is accepted that the in-vitro dissolution delay of about 5 minutes caused by over-encapsulation with gelatin capsules of immediate release (IR) tablets or powder formulation does not lead to non-bioequivalence, no data on bioequivalence exist for over-encapsulation with an HPMC capsule having a dissolution lag time of around 10 minutes. To assess the potential impact, a comparative investigation was performed using in-vitro dissolution, PK simulation and human bioequivalence comparing an IR fixed dose combination compressed caplet containing three different rapidly-absorbed drugs over-encapsulated with gelatin capsules and the same caplet over-encapsulated with HPMC capsules made by a thermo-gelation process.
机译:快速且一致的体内药物溶解对于药物吸收至关重要。体外溶出度测试用于预测药物产品的体内崩解和溶出特性。片剂和胶囊剂的体外崩解和溶解时间可能会因其组成和加工方式而有很大差异。尽管预计体外溶出度的微小差异不会导致显着的体内性能差异,但是对于双盲临床试验而言,通过过度封装以及从明胶换成HPMC胶囊,观察到的轻微的体外溶出延迟会引起人们的关注对体内生物利用度的潜在影响。公认的是,由速释片剂或粉末制剂的明胶胶囊过度包封导致的体外溶解延迟约5分钟不会导致非生物等效性,但对于过度封装,尚无生物等效性的数据HPMC胶囊的溶解滞后时间约为10分钟。为了评估潜在影响,使用体外溶出度,PK模拟和人类生物等效性进行了比较研究,比较了IR固定剂量组合压缩胶囊,其中含有三种不同的快速吸收药物,这些药物被明胶胶囊过度包裹,而同一胶囊被过度包裹通过热凝胶工艺制成的HPMC胶囊。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号